Patents Examined by Cecilia J. Tsang
  • Antibacterial phage peptides and methods of use thereof
    Patent number: 8563504
    Abstract: The present invention is directed to isolated and chimeric polypeptides of bacteriophage origin having antibiotic activity and use thereof in the treatment and control of bacterial infections. Specifically, the present invention is directed to the use of a novel antibacterial polypeptide derived from bacteriophage F87s/06 and chimeric constructs thereof, and their use for the treatment and control of infections caused by gram-positive bacteria, including Staphylococcus aureus.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: October 22, 2013
    Assignee: Lusomedicamenta, S.A.
    Inventors: Miguel Ângelo da Costa Garcia, Madalena Maria Vilela Pimentel, Carlos Jorge Sousa de São José
  • Modulation of platelet aggregation
    Patent number: 8563690
    Abstract: Methods and compositions for inhibition of platelet cell aggregation are described. In particular, compositions comprising cell permeant RGT peptides, such as RGT bound to a lipid moiety are provided. Compositions may be used in the treatment and prevention of clot related diseases such as stroke and myocardial infarction.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: October 22, 2013
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Xiaoping Du, Xiaodong Xi
  • Synthetic lung surfactant and use thereof
    Patent number: 8563683
    Abstract: The present invention relates to synthetic lung surfactant compositions that contain one or more of phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active proteins or peptides, more preferably a combination of at least two or all three of these materials. Novel phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active peptides are also disclosed herein. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue, to prepare synthetic peptides for use in the surfactant compositions, and to deliver therapeutic agents are also disclosed.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: October 22, 2013
    Assignees: University of Rochester, The Los Angeles BioMedical Research Institute at Harbor—UCLA Medical Center, University of Guelph
    Inventors: Robert H. Notter, Zhengdong Wang, Adrian L. Schwan, Zhongyi Wang, Jason A. Davy, Alan J. Waring, Frans J. Walther, Larry M. Gordon
  • Antibiotic, its nucleotide sequence, methods of construction and uses thereof
    Patent number: 8563503
    Abstract: The present invention belongs to field of biology and medicine, and especially relates to a novel antibiotic, its nucleotide sequence, methods of construction and uses thereof. A novel antibiotic, wherein the end of any peptide of the allosteric colicin is connected linearly to the end of peptide of the Staphylococcus aureus pheromone AgrD I, AgrD II, AgrD III, AgrD IV or Staphylococcus epidermidis pheromone. Wherein the allosteric colicin being yielded by artificially mutating the amino acid residues G11A, H22R, A26G, V31L and H40K in the peptide chain of wild type Colicin E1, Ia, Ib, A, B, N, or their ion channel-forming structural domain. In comparison with the traditional antibiotics, the novel antibiotics in the present invention are not likely to lead to drug resistance and cause hypersensitivity reaction.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: October 22, 2013
    Assignee: Protein Design Lab. Ltd.
    Inventor: Xiaoqing Qiu
  • Fluorescent proteins and methods for using same
    Patent number: 8563703
    Abstract: The present invention provides nucleic acid molecules encoding novel red fluorescent proteins from Entacmaea quadricolor and mutants thereof. Also of interest are proteins that are substantially similar to the novel red fluorescent proteins. In addition, host cells, stable cell lines and transgenic organisms comprising the nucleic acid molecules encoding the novel red fluorescent proteins are provided. The subject proteins and nucleic acid compositions find use in a variety of different applications and methods, particularly for labeling of biomolecules, cells, or cell organelles. Finally, kits for use in such methods and applications are provided.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: October 22, 2013
    Assignee: Evrogen IP Joint Stock Company
    Inventors: Sergey A. Lukyanov, Dmitry M. Chudakov
  • Conformationally constrained peptide mimetics
    Patent number: 8563686
    Abstract: Conformationally constrained peptide mimetics in which a hydrogen bond interaction is replaced with a covalent hydrogen bond mimic are provided. Also provided are various methods of making these peptide mimetics.
    Type: Grant
    Filed: August 31, 2009
    Date of Patent: October 22, 2013
    Assignee: Indian Institute of Science
    Inventor: Erode N. Prabhakaran
  • 3-hydroxyisothiazole 1-oxide derivatives
    Patent number: 8557766
    Abstract: [Object] To provide a GPR40 activating agent containing, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the compound or the salt, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of Solving the Problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 2; k is 0 to 1; a ring A is an aryl group, a heterocyclic group, a cycroalkyl group, a cycroalkenyl group, a spirocyclic group; a ring B is an aryl group, a heteroaryl group; X is 0 or —NR7—; and R1 to R7 and L are specific groups), a salt of the compound, or a solvate of the compound or the salt.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: October 15, 2013
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Munetaka Ohkouchi
  • Recombinant proteins having haemostatic activity and capable of inducing platelet aggregation
    Patent number: 8557774
    Abstract: Disclosed herein are recombinant proteins capable of inducing platelet aggregation and uses thereof.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: October 15, 2013
    Assignee: Centre Hospitalier Universitaire de
    Inventors: David Vandroux, Emmanuel De Maistre, Edouard Prost
  • Spatially-defined macrocycles incorporating peptide bond surrogates
    Patent number: 8557765
    Abstract: Novel spatially-defined macrocyclic compounds incorporating peptide bond surrogates are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.
    Type: Grant
    Filed: May 26, 2009
    Date of Patent: October 15, 2013
    Assignee: Tranzyme Pharma Inc.
    Inventors: Pierre Deslongchamps, Yves Dory, Luc Ouellet, Gérald Villeneuve, Mahesh Ramaseshan, Daniel Fortin, Mark L. Peterson, Hamid R. Hoveyda, Sylvie Beaubien, Éric Marsault, Graeme L. Fraser
  • Tyrosine kinase-inducible domains
    Patent number: 8551723
    Abstract: The present invention relates to a tyrosine kinase-inducible domain (pKID) and uses thereof. An isolated polypeptide comprising the pKID, and an isolated polynucleotide comprising a nucleic acid sequence encoding the pKID are provided. Also provided are methods for determining tyrosine kinase and/or phosphatase activity in a sample and for identifying an agent that inhibits a tyrosine kinase or phosphatase using a polypeptide comprising the pKID.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: October 8, 2013
    Assignee: University of Delaware
    Inventors: Neal J. Zondlo, Susan Carr Zondlo, Feng Gao
  • Peptide having an extending action for half-life of object peptide in plasma
    Patent number: 8551937
    Abstract: An isolated chimeric peptide consisting of one or two added peptides and an object peptide wherein the added peptide is bonded to the N-terminus, the C-terminus or both of the object peptide, wherein if the added peptides are bound to both terminals, the two added peptides may be the same or different; and physiological activity of the object peptide is still retained, wherein the object peptide is a natural physiologically active peptide selected from the group consisting of an atrial natriuretic peptide, a brain natriuretic peptide, a C-type natriuretic peptide, motilin, a glucagon-like peptide 1, parathyroid hormone, and calcitonin, or a derivative of any thereof, wherein the derivative has one or more amino acid(s) deleted from the amino acid sequence of a natural physiologically active peptide and has the desired physiological activity.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: October 8, 2013
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Naomi Wakabayashi, Seiji Sato
  • NPR-B agonists
    Patent number: 8551938
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: October 8, 2013
    Assignee: Alcon Research, Ltd.
    Inventors: Mark R. Hellberg, Iok-Hou Pang
  • Peptide analogues, particularly for the treatment of chronic pain
    Patent number: 8551939
    Abstract: The use is claimed of opioid peptides with a novel structure, which in addition to the pharmacophore contain structural elements that interact with neurotensisn receptors. Due to the synergistic interaction with the additional element, an augmented analgesic activity is obtained, capable of being used for an extended period due to decreased drug tolerance induction. These compounds may be of particular use in the treatment of chronic pain as effective analgesics during inflammation caused by rheumatoid, gout, neurodegeneration, post-operative or post-accidental lesions, or oncogenic lesions.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: October 8, 2013
    Assignee: Instytut Medycyny Doswiadczalnej I Klinicznej
    Inventor: Andrzej Lipkowski
  • NPR-B agonists
    Patent number: 8546523
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: October 1, 2013
    Assignee: Alcon Research, Ltd.
    Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Uwe Richter, Bernadett Simon, Edgar Specker, Markus Woischnik, Mark R. Hellberg
  • Pipecolic linker and its use for chemistry on solid support
    Patent number: 8546533
    Abstract: The present invention relates to a pipecolic linker and its use as a solid-phase linker in organic synthesis. Said pipecolic solid-phase linker may be used for coupling functional groups chosen between primary amines, secondary amines, aromatic amines, alcohols, phenols and thiols. In particular, said pipecolic solid-phase linker may be used for peptide or pseudopeptide synthesis, such as the reverse N to C peptide synthesis or the retro-inverso peptide synthesis, or for the synthesis of small organic molecules.
    Type: Grant
    Filed: August 28, 2009
    Date of Patent: October 1, 2013
    Assignees: Centre National de la Recherche Scientifique (CNRS), Universite de Montpellier 1, Universite Jagellone, Universite Montpellier 2—Sciences et Techniques
    Inventors: Jean Martinez, Pawel Zajdel, Maciej Pawlowski, Gilles Subra
  • Self-assembling hydrogels based on dicephalic peptide amphiphiles
    Patent number: 8546338
    Abstract: We have disclosed dicephalic amphiphiles having peptide sequences as the head groups. We have also disclosed self-assembly hydrogels prepared from the dicephalic peptide amphiphiles. These hydrogels are useful for the encapsulation and delivery of bioactives to a patient.
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: October 1, 2013
    Assignee: Johnson & Johnson Consumer Companies, Inc.
    Inventors: Jackie J. Donners, Aruna Nathan
  • Use of a composition comprising a non-fermented rice peptidic hydrolyzate for stimulating hair growth
    Patent number: 8541374
    Abstract: The present invention relates to the use of a composition comprising at least one non-fermented rice peptidic hydrolyzate as an active agent for slowing down and limiting hair loss and/or stimulating hair growth. Said composition is also intended to protect the follicular adult stem cells as well as their specific microenvironment. In addition, the composition according to the invention combats the aging and particularly the photoaging of hair. Lastly, the present invention relates to several non-therapeutic treatment methods utilizing said composition.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: September 24, 2013
    Assignee: ISP Investments Inc.
    Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
  • Use of a octreotide as a therapeutic agent
    Patent number: 8541364
    Abstract: The present invention is directed to the use of the peptide compound D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
    Type: Grant
    Filed: September 9, 2008
    Date of Patent: September 24, 2013
    Assignee: Mondobiotech Laboratories AG
    Inventors: Dorian Bevec, Fabio Cavalli, Vera Cavalli, Gerald Bacher
  • Composition
    Patent number: 8541361
    Abstract: The present invention relates to compositions comprising a peptide with 2-12 amino acids substituted with a lipophilic moiety and a water soluble salt of an alkali, earth alkaline metal or transition metal. Furthermore, the invention relates to a container comprising such compositions. Additionally, the invention relates to the use of a water soluble salt of an alkali, earth alkaline metal or transition metal for reducing the adhesion of a peptide with 2-12 amino acids substituted with a lipophilic moiety to a surface.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: September 24, 2013
    Assignee: DSM IP Assets B.V.
    Inventors: Marc Heidl, Roman Wille, Hugo Ziegler
  • Isolated extracellular matrix material including subserous fascia
    Patent number: 8541372
    Abstract: Described are purified extracellular matrix materials isolated from the abdominal wall of animals and including the subserous fascia layer of the abdominal wall. Such medical materials can find use in treating damaged tissue and in certain aspects in providing tissue support for the repair of hernias. Related methods of manufacture and use are also described.
    Type: Grant
    Filed: January 3, 2011
    Date of Patent: September 24, 2013
    Assignee: Cook Biotech Incorporated
    Inventors: Bhavin Shah, Katie L. Harrigan